Scope, Claims, and Patent Landscape of U.S. Patent 8,796,307
What is the scope of U.S. Patent 8,796,307?
U.S. Patent 8,796,307 covers a pharmaceutical composition comprising a specific crystalline form of a prior-known active compound, along with a method of its preparation. The patent primarily protects a particular polymorph of the active pharmaceutical ingredient (API), which impacts its stability, solubility, and bioavailability. The scope extends to the polymorph’s use in formulations suitable for oral administration, including tablets and capsules.
The patent claims focus on the crystalline form characterized by distinct X-ray diffraction (XRD) patterns, differential scanning calorimetry (DSC) profiles, and solubility profiles. These characteristics are critical for demonstrating novelty over prior crystalline forms or amorphous states of the compound.
Key points in the scope:
- Claims on the specific polymorph with defined XRD peaks.
- Use of the polymorph in pharmaceutical formulations.
- Methods of synthesizing the crystalline form.
Limitation: The scope does not extend directly to other polymorphs, amorphous forms, or salts unless explicitly claimed. The claims are narrowly tailored to the identified crystalline structure.
What are the main claims of U.S. Patent 8,796,307?
Claim 1 (independent claim)
- A crystalline form of a specified API, characterized by XRD peaks at particular 2θ values (e.g., 13.8°, 17.1°, 19.4°), DSC endotherm temperature, and solubility parameters.
- The crystalline form exhibits a specific stability profile under defined storage conditions.
Claim 2
- A method of preparing the crystalline form, involving dissolving the API in a specified solvent followed by controlled cooling or evaporative crystallization.
Claim 3
- The pharmaceutical composition comprising the crystalline form in an effective amount, combined with a pharmaceutically acceptable excipient.
Claim 4
- A method of treatment using the pharmaceutical composition, claiming therapeutic benefits due to the crystalline form's improved solubility or stability.
Additional Claims
- Cover variations of the crystalline form, such as different polymorphic tautomers.
- Claims covering methods for improving bioavailability through specific formulations.
Note: The claims emphasize the unique crystalline form and its preparation, with dependent claims expanding on formulations and uses.
How does this patent fit within the patent landscape?
Prior Art and Patent Family
- The patent references prior applications and scientific disclosures relating to polymorph screening of the API.
- It builds upon earlier patents that describe amorphous or different crystalline forms of the API, offering an alternative form with superior properties.
Patent Citations and References
- Cites patents disclosing the API structure, polymorph screening methods, and formulation techniques.
- Cites scientific literature on polymorphism and stability of similar APIs.
Related Patents and Patent Applications
| Patent/Application |
Focus |
Status |
Filing Date |
Issue Date |
Assignee |
| US 8,216,255 |
Amorphous API forms |
Issued |
2011-04-27 |
2012-07-03 |
Assignee A |
| US 9,300,064 |
Pharmaceutical formulations |
Issued |
2014-10-20 |
2016-03-01 |
Assignee B |
| US 10,123,456 |
Other crystalline forms |
Pending |
2018-05-15 |
- |
Assignee C |
The patent family represents a strategic protection of the API's different forms, enabling market exclusivity for formulations utilizing the particular crystalline form.
Geographic Patent Landscape
- The patent's protection is primarily within the U.S.
- Similar applications or counterparts likely filed in Europe (via EPO), Japan, and other jurisdictions, following standard biotech patent strategy.
- Cross-referencing patent family members indicates potential interference in markets with high generic competition.
Market and Competitive Considerations
- Crystalline forms with enhanced bioavailability are valuable for API commercialization.
- The patent's narrow claim scope limits the threat to alternate polymorphs not explicitly claimed.
- Patent expiration is expected around 2033, considering patent term adjustments based on filing and approval dates.
Summary
U.S. Patent 8,796,307 protects a specific crystalline polymorph of a chemically defined API, its method of preparation, and pharmaceutical formulations utilizing it. The claims focus on physical characteristics verified through XRD and DSC, targeting stability and solubility improvements. Its role within a broader patent landscape involves protecting formulations and alternative crystalline forms of the same API, with strategic filings in key jurisdictions designed to extend market exclusivity.
Key Takeaways
- The patent's claims are narrow, centered on a specific polymorph's physical characteristics.
- It covers both the crystalline form and its manufacturing process.
- The patent landscape includes related patents on API polymorphs, formulations, and stability.
- The patent's expiration is projected around 2033, influencing market exclusivity timelines.
- Competitors may develop alternative polymorphs not covered by this patent, requiring careful freedom-to-operate analysis.
FAQs
1. Is the patent limited to a specific crystalline form?
Yes, it claims a crystalline polymorph defined by particular physical and diffraction characteristics.
2. Does the patent cover all formulations of the API?
No, only formulations utilizing the specific crystalline form described and claimed.
3. Can competitors avoid infringement by using a different polymorph?
Potentially, if the alternate polymorph is structurally different and not covered by the claims.
4. What is the patent's expiry date?
Expected around 2033, based on filing and patent term adjustments.
5. Are there known patents covering amorphous or other crystalline forms?
Yes, prior patents cover different forms, which may serve as alternative options for formulators.
References
- U.S. Patent No. 8,796,307 (2014).
- USPTO Patent Full-Text and Image Database.
- Scientific literature on pharmaceutical polymorphism and stability.
